X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare IPCA Labs with Abbott India - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

IPCA LABS vs ABBOTT INDIA - Comparison Results

IPCA LABS    Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

ABBOTT INDIA 
   Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    IPCA LABS ABBOTT INDIA IPCA LABS/
ABBOTT INDIA
 
P/E (TTM) x 42.8 43.3 98.9% View Chart
P/BV x 3.3 10.8 30.4% View Chart
Dividend Yield % 0.2 0.6 25.2%  

Financials

 IPCA LABS   ABBOTT INDIA
EQUITY SHARE DATA
    IPCA LABS
Mar-17
ABBOTT INDIA
Mar-16
IPCA LABS/
ABBOTT INDIA
5-Yr Chart
Click to enlarge
High Rs6436,015 10.7%   
Low Rs5033,707 13.6%   
Sales per share (Unadj.) Rs254.41,236.9 20.6%  
Earnings per share (Unadj.) Rs16.1122.2 13.2%  
Cash flow per share (Unadj.) Rs29.8129.0 23.1%  
Dividends per share (Unadj.) Rs1.0035.00 2.9%  
Dividend yield (eoy) %0.20.7 24.2%  
Book value per share (Unadj.) Rs194.6521.2 37.3%  
Shares outstanding (eoy) m126.2021.25 593.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.33.9 57.3%   
Avg P/E ratio x35.739.8 89.6%  
P/CF ratio (eoy) x19.237.7 51.1%  
Price / Book Value ratio x2.99.3 31.6%  
Dividend payout %6.228.6 21.7%   
Avg Mkt Cap Rs m72,300103,296 70.0%   
No. of employees `00013.33.0 450.0%   
Total wages/salary Rs m6,9603,370 206.5%   
Avg. sales/employee Rs Th2,413.58,891.8 27.1%   
Avg. wages/employee Rs Th523.21,140.0 45.9%   
Avg. net profit/employee Rs Th152.4878.3 17.4%   
INCOME DATA
Net Sales Rs m32,10626,284 122.2%  
Other income Rs m226504 44.7%   
Total revenues Rs m32,33226,789 120.7%   
Gross profit Rs m4,4483,665 121.3%  
Depreciation Rs m1,730144 1,197.7%   
Interest Rs m2418 2,972.8%   
Profit before tax Rs m2,7034,017 67.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m6751,421 47.5%   
Profit after tax Rs m2,0282,596 78.1%  
Gross profit margin %13.913.9 99.3%  
Effective tax rate %25.035.4 70.6%   
Net profit margin %6.39.9 63.9%  
BALANCE SHEET DATA
Current assets Rs m17,34014,446 120.0%   
Current liabilities Rs m9,5594,725 202.3%   
Net working cap to sales %24.237.0 65.5%  
Current ratio x1.83.1 59.3%  
Inventory Days Days10051 195.1%  
Debtors Days Days5720 290.7%  
Net fixed assets Rs m20,7791,113 1,867.1%   
Share capital Rs m252213 118.8%   
"Free" reserves Rs m24,49910,808 226.7%   
Net worth Rs m24,55311,076 221.7%   
Long term debt Rs m3,5170-   
Total assets Rs m39,59516,241 243.8%  
Interest coverage x12.2497.0 2.5%   
Debt to equity ratio x0.10-  
Sales to assets ratio x0.81.6 50.1%   
Return on assets %5.716.0 35.7%  
Return on equity %8.323.4 35.2%  
Return on capital %10.536.3 28.9%  
Exports to sales %48.60.6 7,911.7%   
Imports to sales %14.212.6 112.6%   
Exports (fob) Rs m15,617162 9,664.2%   
Imports (cif) Rs m4,5713,322 137.6%   
Fx inflow Rs m15,617268 5,827.4%   
Fx outflow Rs m5,8283,927 148.4%   
Net fx Rs m9,790-3,659 -267.5%   
CASH FLOW
From Operations Rs m2,7642,514 109.9%  
From Investments Rs m-1,432-800 179.1%  
From Financial Activity Rs m-1,591-803 198.2%  
Net Cashflow Rs m-259912 -28.4%  

Share Holding

Indian Promoters % 45.9 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 11.4 7.9 144.3%  
FIIs % 25.3 0.1 25,300.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.4 17.1 101.8%  
Shareholders   36,892 18,270 201.9%  
Pledged promoter(s) holding % 2.1 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare IPCA LABS With:   CADILA HEALTHCARE  ELDER PHARMA  SUVEN LIFE  PANACEA BIOTECH  WOCKHARDT LTD.  

Compare IPCA LABS With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Of Mr Modi Providing Impetus to Defense Industry and Key Stocks in Action Today(Pre-Open)

Addressing the Uttar Pradesh Investors Summit, Mr. Modi announced the creation of a defense industrial corridor in Bundelkhand.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

IPCA LABS SHARE PRICE


Feb 21, 2018 (Close)

TRACK IPCA LABS

  • Track your investment in IPCA LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

IPCA LABS 8-QTR ANALYSIS

COMPARE IPCA LABS WITH

MARKET STATS